Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-10-07 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report types. There is no indication of a full report, announcement, or detailed financial data. Given the lack of content and the presence of digital signatures, this document is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-10-07 English
Intimation of Loss of Share Certificate by Shareholder.
Regulatory Filings Classification · 95% confidence The document text is extremely short (1012 characters) and contains only digital signature information without any substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, regulatory body, or corporate event. Given the lack of content and the nature of the text, it does not fit into any specific filing category and is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit elsewhere.
2022-10-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership agreement between Lupin Limited and global agencies to increase access to tuberculosis prevention treatment. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to material events or information. The content focuses on a business development and partnership announcement rather than financial results, management changes, or regulatory filings. It does not contain financial statements, earnings data, or detailed management discussion. The document is not a report but a disclosure of a significant corporate event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-07 English
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment.
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 7, 2022, from Lupin Limited announcing a partnership with global agencies to increase access to tuberculosis prevention treatment. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content focuses on a business partnership and product availability, not on financial results, management changes, or regulatory filings. It is not a financial report, earnings release, or management discussion. The document is a corporate announcement about a strategic partnership and product rollout, which fits best under Capital/Financing Update (CAP) as it relates to business development and strategic agreements impacting company operations and potentially capital structure or market positioning. The document length is 5348 characters, sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2022-10-07 English
Press Release
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a new Global Chief Scientific Officer at Lupin Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information. The content focuses on management change, specifically the appointment of a senior executive, and includes biographical details and company background. There are no financial statements, earnings data, or detailed reports included. The document length is 4012 characters, which is relatively short and typical for a management change announcement. Therefore, this document fits the category of Board/Management Information (MANG).
2022-10-06 English
Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer.
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer of Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on management appointment and does not contain financial data, earnings, or detailed reports. The document length is 4631 characters, which is relatively short and typical for a management change announcement. Therefore, the document fits the category of Board/Management Information (MANG).
2022-10-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.